MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $100.00 price objective on the stock. HC Wainwright's price objective suggests a potential upside of 151.83% from the stock's previous close. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.62) EPS.
MLTX has been the topic of several other reports. Wedbush restated an "outperform" rating and issued a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. The Goldman Sachs Group raised MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the company from $62.00 to $82.00 in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $83.20.
Get Our Latest Stock Analysis on MLTX
MoonLake Immunotherapeutics Price Performance
Shares of MLTX traded down $2.05 during trading hours on Thursday, hitting $39.71. The stock had a trading volume of 218,019 shares, compared to its average volume of 434,238. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -30.78 and a beta of 1.28. MoonLake Immunotherapeutics has a 52 week low of $37.55 and a 52 week high of $58.26. The company's fifty day moving average is $46.49 and its two-hundred day moving average is $48.95.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.09). Equities analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.
Institutional Investors Weigh In On MoonLake Immunotherapeutics
Several institutional investors have recently made changes to their positions in MLTX. Congress Asset Management Co. bought a new position in MoonLake Immunotherapeutics in the third quarter valued at approximately $3,360,000. US Bancorp DE bought a new position in shares of MoonLake Immunotherapeutics during the third quarter worth about $44,000. Rice Hall James & Associates LLC acquired a new position in MoonLake Immunotherapeutics in the third quarter valued at $3,805,000. Harbor Capital Advisors Inc. boosted its holdings in shares of MoonLake Immunotherapeutics by 100.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 77,468 shares of the company's stock worth $3,906,000 after buying an additional 38,779 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter worth about $706,000. 93.85% of the stock is currently owned by institutional investors.
About MoonLake Immunotherapeutics
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Read More

Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.